FDA
-
-
-
-
-
-
-
Xeris receives Orange Book listing for Recorlev patent extending to 2040
-
-
-
-
-
-
-
Xeris Pharmaceuticals (XERS) PT Raised to $6.60 at H.C. Wainwright
-
-
-
-
-
-
-
Xeris Biopharma Reports Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023
-
-
-
-
-
-
-
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism
-
-
-
-
-
-
-
Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast
-
-
-
-
-
-
-
Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

